- Home
- LVLU vs PSTV Comparison
LVLU vs PSTV Comparison
Compare LVLU & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVLU | PSTV |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.6M | 34.5M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | LVLU | PSTV |
|---|---|---|
| Price | $7.59 | $4.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $55.00 |
| AVG Volume (30 Days) | 5.9K | ★ 130.7K |
| Earning Date | 05-13-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,284,000.00 | $5,213,000.00 |
| Revenue This Year | $5.66 | $13.20 |
| Revenue Next Year | N/A | $261.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.22 | $0.13 |
| 52 Week High | $32.32 | $8.00 |
Technical Indicators
Market Signals| Indicator | LVLU | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 29.40 | 31.84 |
| Support Level | $7.23 | $0.37 |
| Resistance Level | $11.21 | $6.65 |
| Average True Range (ATR) | 0.91 | 0.45 |
| MACD | -0.08 | -0.19 |
| Stochastic Oscillator | 2.25 | 0.00 |
Price Performance
Historical ComparisonAbout LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).